Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relfydess for horizontal forehead lines
ACTRN12626000192381Phase 4Not yet recruiting
- Sponsor
- Dermatological Institute of Victoria
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of relugolix + estradiol + norethindrone in wrinkle (2 arms), sponsored by Dermatological Institute of Victoria. Primary endpoint: Mean change in forehead wrinkle severity from baseline. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
relugolix + estradiol + norethindrone
03
Conditions
wrinkle
Beyond the preview
Go deeper on ACTRN12626000192381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000192381.